Anthropic has launched Claude Science, an AI platform tailored for pharmaceutical researchers. The system goes beyond traditional assistance by autonomously executing complex tasks, streamlining workflows for drug discovery.
According to Zubair Jandali, head of Anthropic’s healthcare division, the platform can operate independently, handling tasks like screening drug compounds from a single instruction. This mirrors advancements in software development, where AI has evolved from basic autocomplete to full autonomy.
The technology integrates databases, lab tools, and computing resources into a unified interface, enabling researchers to delegate multi-step analyses to the AI. This could significantly accelerate drug development timelines, which currently span an average of 12 years, by addressing information and operational delays.
Anthropic’s co-founder, Vas Narasimhan, notes that while AI can nearly eliminate information latency—making data instantly accessible—biological testing remains a manual process. He estimates AI could cut approval timelines to seven or eight years and double success rates in drug development, which typically stand at 8%.
However, Narasimhan acknowledges limitations, stating that AI cannot yet determine if a biological target is viable for drug intervention—a critical hurdle in pharma research.
Bristol Myers Squibb’s CEO, Chris Boerner, echoes this caution, warning against overpromising AI’s capabilities. He highlights BMS’s current use of AI for screening small and large molecule candidates, aiming for a 30% reduction in development cycles—progress they believe is already underway.
Also Read
- The FDA Already Approved This Fall’s COVID Vaccine Strain, but No One Has Officially Said Who Should Get It
- LA County Issues a Health Alert as 150,000 Fans Are Expected at SoFi Stadium During Pride Month
- Neurological Research Update: Brain Lesions, Dementia Biomarkers, and Multiple Sclerosis Findings
- Researchers Identify Key Protein Driving the Spread of Alzheimer’s Throughout the Brain